Latest news
24 May 2023
Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK
Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London. Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines. Expansion follows recent acceptance of … Continued
18 April 2023
20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project
Enschede, The Netherlands, and Hampton, UK – April 18, 2023 – 20Med Therapeutics, a leader in non-viral delivery and development of gene therapies and vaccines, and Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced that both parties will collaborate on establishing a novel vaccination platform that combines … Continued
29 March 2023
Touchlight secures government grant to support its £14m investment in scale-up DNA manufacturing
Hampton, UK, 29 March 2023 – Touchlight, a CDMO pioneering enzymatic DNA production to enable genetic medicines, today announced that it has secured a grant from the Department for Science, Innovation and Technology to support the acceleration of its £14m scale-up DNA manufacturing programme. The grant comes from the £277 million in joint government and … Continued
28 February 2023
Touchlight announces first FDA clearance of an IND utilising doggybone DNA
Enzymatic doggybone DNA material used in GMP production of a cell therapy by a US-based client. Major landmark demonstrates the clinical adoption of Touchlight’s proprietary technology across modalities. Hampton, UK, 28 February 2023 – Touchlight, a CDMO pioneering enzymatic DNA production to enable genetic medicines, today announced the first FDA clearance of an Investigational New Drug (IND) … Continued
24 January 2023
FDA accepts Drug Master File, signifying a new milestone for Touchlight’s enzymatic doggybone DNA technology
Drug Master File simplifies the U.S. regulatory process for utilising Touchlight’s doggybone DNA and accelerates regulatory filings. doggybone DNA is the first enzymatic DNA platform with a Drug Master File, representing a significant step towards regulatory adoption. Hampton, UK, 24 January 2023 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced … Continued
7 December 2022
Touchlight and Odimma Therapeutics announce clinical material supply agreement to develop personalised cancer therapy utilising doggybone DNA
Touchlight and Odimma have entered into an agreement to develop and supply clinical material for Odimma’s neoantigen program Hampton, UK, 7 December 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announces a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalised cancer immunotherapy. … Continued
29 November 2022
Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform
Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses. Hampton, UK – 29 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development … Continued
15 November 2022
Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform
Hampton, UK, 15 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a patent license agreement with Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids. Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in … Continued
26 September 2022
Touchlight awarded Innovate UK grant for the measurement and intracellular visualisation of synthetic DNA constructs
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has been awarded an Innovate UK grant enabling it to work, alongside partners, at addressing the measurement and intracellular visualisation of synthetic DNA constructs. With the development of new DNA-based therapies and technologies the demand for nucleic acid products continues to … Continued
6 September 2022
Lonza and Touchlight collaborate on end-to-end mRNA offering
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNA). Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability. Customers can gain access to Touchlight’s dbDNA as an integral part of Lonza’s offering, benefiting from end-to-end mRNA … Continued
22 August 2022
Touchlight awarded ILAP for therapeutic DNA vaccine
Touchlight has been officially awarded an Innovation Passport through Innovative Licensing and Access Pathway (ILAP) for its therapeutic DNA vaccine, a vaccine that targets head and neck squamous cell carcinoma (HNSCC). ILAP is a novel pathway formed by the MHRA, NICE, SMC, and the AWTTC, supporting innovative approaches to the safe, timely and efficient development … Continued
6 July 2022
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies
Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies Agreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercialization Access to dbDNA patent rights enables Pfizer’s rapid production of … Continued
Upcoming events
ASGCT Annual Meeting 2023
Join us at ASGCT, Los Angeles (May 16-18, 2023).
Our team will be available at booth #507 to discuss your advanced therapy manufacturing. Learn how our enzymatically produced DNA vector called doggybone DNA (dbDNA) can significantly improve speed to manufacture, safety and scalability in comparison to plasmid DNA, for vaccine development.
Learn more